Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence

Jinliang Yu; Zhiyuan Sheng; Shuang Wu; Yushuai Gao; Zhaoyue Yan; Chaojie Bu; Jianjun Gu; Yage Bu; Kaiyuan Deng; Sensen Xu; Zhongcan Chen; Qianqian Zhang; Ajmal Zemmar; Juha Hernesniemi; Meiyun Wang; Gang Liu; Tianxiao Li; Xingyao Bu

doi:10.3389/fonc.2021.742037

Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence

Front Oncol. 2021 Oct 11:11:742037. doi: 10.3389/fonc.2021.742037. eCollection 2021.

Authors

Jinliang Yu¹, Zhiyuan Sheng^{2

3}, Shuang Wu^{2

3}, Yushuai Gao^{2

3}, Zhaoyue Yan^{2

3}, Chaojie Bu^{3

4}, Jianjun Gu^{3

4}, Yage Bu^{2

3}, Kaiyuan Deng^{2

3}, Sensen Xu^{2

3}, Zhongcan Chen^{3

4}, Qianqian Zhang⁴, Ajmal Zemmar⁴, Juha Hernesniemi^{3

4}, Meiyun Wang^{5

6}, Gang Liu⁷, Tianxiao Li^{3

4}, Xingyao Bu^{2

3}

Affiliations

¹ Department of Neurosurgery, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
² Department of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
³ Juha International Central Laboratory of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou, China.
⁴ Juha International Center for Neurosurgery, Henan Provincial People's Hospital, Zhengzhou, China.
⁵ Department of Medical Imaging, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China.
⁶ Henan Provincial Key Laboratory for Imaging Diagnosis and Research of Neurological Diseases, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China.
⁷ Department of Center for Clinical Single Cell Biomedicine, Clinical Research Center, Department of Oncology, Henan Provincial People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (TISF-DNA) can detect genomic changes in recurrent tumors and facilitate recurrence risk analysis, providing valuable information for diagnosis and prognosis. The tumor DNA in TISF is more representative and sensitive than that in cerebrospinal fluid. It reveals the mutational landscape of minimal residual disease after glioma surgery and the risk of early recurrence, contributing to the clinical management and clinical research of glioma patients.

Keywords: circulating tumor DNA; glioma progression; precision medicine; spatiotemporal heterogeneity; tumor in-situ fluid.